Use of dexamethasone, rosiglitazone, and 3-isobutyl-1-methylxanthine composition in the preparation of drugs for inhibiting the growth and metastasis of ovarian cancer cells induced by cobalt chloride

A kind of technology of methylxanthine and ovarian cancer cells, applied in the field of a method and special pharmaceutical composition

Active Publication Date: 2022-02-18
TIANJIN PEOPLE HOSPITAL
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research work on the induction of solid tumor differentiation is still in the application stage. The application of certain chemical substances can reverse the immature malignant cells and differentiate into normal cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of dexamethasone, rosiglitazone, and 3-isobutyl-1-methylxanthine composition in the preparation of drugs for inhibiting the growth and metastasis of ovarian cancer cells induced by cobalt chloride
  • Use of dexamethasone, rosiglitazone, and 3-isobutyl-1-methylxanthine composition in the preparation of drugs for inhibiting the growth and metastasis of ovarian cancer cells induced by cobalt chloride
  • Use of dexamethasone, rosiglitazone, and 3-isobutyl-1-methylxanthine composition in the preparation of drugs for inhibiting the growth and metastasis of ovarian cancer cells induced by cobalt chloride

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] 1 malignant tumor cells are ovarian cancer hey cell lines and breast cancer MDA-MB-231 cell lines; in vitro-induced hephocytes and MDA-MB-231 cell fat differentiation methods are:

[0072] High concentration CoCl 2 Inducing the cell lines to obtain high violation transfer capabilities: Among the ovarian cancer cell lines, 535.5 μl of COCL using RPMI-1640 medium 2 After 48 h, replace the RPMI-1640 medium; breast cancer cell line MDA-MB-231 use DMEM medium 5ml + plus 535.5μL COCL 2 After 33 hours, DMEM medium is replaced; observe the state of the cells, replace fresh medium, and the cell will return to 10-14 days, when CoCl 2 When the resiliency of the cell recovery fusion is 80% -90%, the same concentration CoCl is again used. 2 Treatment of the same time, after a high concentration CoCl 2 After repeated treatment 2 times, a sufficient number of cells are obtained.

[0073] 2 will pass through in vitro-induced control group cells and COCL 2 Inducible cells, use excluding COC...

Embodiment 2

[0085] Construct nude murine transplanted tumor model

[0086] Control group cells and COCLs will pass through in vitro in vitro 2 The induced cell subcutaneous injection of 6-8 weeks old BALB / C immunodeficiency female rats were subcutaneously constructed under subcutaneous mice. Mouse transplanted tumors were carried out to induce ovarian cancer hey cell lines, and the fat cells obtained by the breast cancer MDA-MB-231 cell line had a normal fat cellular molecular label and stably exist in the mouse transplanted tumor model.

[0087] When constructing naked mouse transplanted tumor model, take 20 BALB / CNU / NU Nude Mouse (Beijing Virong Lihua Experimental Animal Technology Co., Ltd.), all of which are 6-8 weeks old, female, accommodation between SPF-level nude mice For around the week, 5 / cage, a total of 6 cages, replacement of rat cages during feeding, pay attention to feed, gasket, water source and murine cage; prepare for any ordinary hey tumor cells, COCL 2 After treatm...

Embodiment 3

[0106] The final concentration and therapeutic dose of the animal experimental drug composition (DRI):

[0107] (1) 21 days 21 in each group of nude mice, each group of tumors exceeded 100mm 3 Afterwards, Hey cells tumor group, COCL 2 The treated cell group was randomly divided into pharmaceutical composition (DRI) treatment group, DMSO control group, and blank control group.

[0108] (2) Exploring the treatment of different drugs in the DRI treatment group: According to the LD50, IC50, EC50 of three small molecular compounds, preferably three drug therapeutic doses: dexamethasone (10 mm × 1 ml dissolved in DMSO) Treatment Dose: 1.77- 4.17 μg / 25g mouse weight; Rosiglitazone (10 mM × 1 mL dissolved in DMSO) Treatment dose: 400-625 μg / 25g mice weight; 3-isobutyl-1-methyl xanthine (10 mm × 1 mL is dissolved in Treatment dose: 180.57-275 μg / 25g mice weight.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for inhibiting the growth and metastasis of solid tumor cells and a special pharmaceutical composition, belonging to the field of animal cell proliferation and transformation. When the present invention induces ovarian cancer HEY cells or breast cancer MDA‑MB‑231 cells, the culture medium is treated with a high concentration of CoCl 2 After the effect, the medium was replaced, and after the cells recovered, the treatment was repeated twice to obtain a sufficient number of cells with high invasion and metastasis capabilities; the obtained cells were treated again without CoCl 2 culture medium, and then add a pharmaceutical composition consisting of dimethyl sulfoxide, dexamethasone, rosiglitazone, and 3-isobutyl-1-methylxanthine to the removed medium for in vitro induction , when the formation of lipid droplets in the tumor cell plasma was obvious, it indicated that the tumor cells were adipose differentiated. The invention designed in this way induces fat differentiation of tumor cells and achieves the purpose of inhibiting the growth of tumor cells. It has been confirmed by animal experiments that it is expected to be used for clinical treatment and metastasis suppression of human solid tumors.

Description

Technical field [0001] The present invention relates to the proliferation transformation of animal cells, in particular a method of inhibiting physical tumor cell growth transfer and a dedicated pharmaceutical composition. Background technique [0002] Tumors are a systemic systemic disease and is a disease with the highest morphogenetic rate and mortality. At present, the main methods for preventing tumors prevention and treatment include surgical surgery, placing, chemotherapy. Compared with surgical treatment and radiation treatment, drug treatment is a systemic effect, and traditional chemotherapy drugs are not only killed in tumor cells, but also have a killing effect on normal body cells. The toxicity and drug resistance is not to neglect. In addition, chemotherapy drugs can also induce tumor cell invasion and metastasis capacity enhancement, and tumor cells have enhanced the tolerance of chemotherapy drugs, which ultimately leads to recurrence and metastasis of tumors. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4439A61K31/573A61K31/522A61P35/00C12N5/09
CPCA61K31/4439A61K31/573A61K31/522A61P35/00C12N5/0693
Inventor 张诗武张可昕李玉玮
Owner TIANJIN PEOPLE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap